47 results on '"Park, Su-Hyung"'
Search Results
2. Supplementary Figures S1-11 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
3. Supplementary Tables S1-7 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
4. Supplementary Figures S1-11 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
5. Supplementary Tables S1-7 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
6. Supplementary Figures S1-11 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
7. Data from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
8. Supplementary Figures S1-11 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
9. Supplementary Tables S1-7 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
10. Supplementary Tables S1-7 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
11. Supplementary Figure 6 from YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
12. Supplementary Figure 2 from YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
13. Supplementary Figure 3 from YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
14. Data from YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
15. Supplementary Figure 4 from YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
16. Supplementary Figure 6 from YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
17. Supplementary Figure 3 from YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
18. Supplementary Figure 4 from YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
19. Supplemental figure legends and table from YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
20. Supplementary Figure 5 from YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
21. Data from YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
22. Supplementary Figure 5 from YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
23. Supplementary Figure 1 from YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
24. Supplementary Figure 2 from YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
25. Supplemental figure legends and table from YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
26. Supplementary Figure 1 from YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
27. Supplementary Figures S1-11 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
28. Supplementary Table S2 from PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
29. Supplementary Table S1 from PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
30. Supplementary Data from PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
31. Supplementary Table S4 from PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
32. Supplementary Table S3 from PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
33. Supplementary Data from Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma
34. Supplementary Data from Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma
35. Supplementary Figure S1 from The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors
36. Supplementary Figures S1-S21 from PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
37. Supplementary Data from Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma
38. Supplementary Data from PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
39. Supplementary Data from Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma
40. CEACAM1 marks highly suppressive intratumoral regulatory T cells for targeted depletion therapy
41. Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma
42. Correction: The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors
43. Tumor-Infiltrating Regulatory T-cell Accumulation in the Tumor Microenvironment Is Mediated by IL33/ST2 Signaling
44. PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
45. Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8+ T Cells is Determined by Their Differentiation Status in Glioblastoma
46. The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors
47. YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.